Biomerieux (BIM.PA) Stock Price
Biomerieux Price
Revenue has compounded at 7.5% per year over the past 19 years to 4.07 B EUR. Earnings per share have grown at 7.2% per year over the last 19 years. Biomerieux's net margin stands at 9.8%, down from 17.8% several years earlier. Biomerieux currently offers a dividend yield of about 1.01%. The payout ratio is around 27% of earnings. The dividend has grown at 9.8% per year over the past 19 years. Analysts set a median price target of 121.38 EUR, implying 36.1% above the current price. Of 17 analysts, 10 rate the stock a buy — an overall Buy consensus.
Biomerieux stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Biomerieux business model & stock analysis
Frequently asked questions about Biomerieux
The business model of Biomerieux SA is focused on diagnostic solutions for infectious diseases and cancer. The company develops and manufactures in vitro diagnostic tests, instruments, and software that aid in detecting diseases and guiding patient treatment. Biomerieux's comprehensive portfolio caters to clinical laboratories, hospitals, and industrial microbiology laboratories globally. Their solutions include microbiology, immunoassays, molecular biology, and blood culture systems. By leveraging cutting-edge technologies, Biomerieux aims to improve patient outcomes and enhance public health through early and accurate diagnosis. With a strong emphasis on research and innovation, the company continues to lead in the field of clinical diagnostics, offering reliable and efficient solutions for healthcare professionals worldwide.
Biomerieux SA is primarily active in the diagnostics industry.
The main competitors of Biomerieux SA in the market include companies like Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, and QIAGEN N.V.
Biomerieux SA, a leading global player in the field of in vitro diagnostics, has a rich history and background. The company was founded in 1963 by Dr. Alain Merieux with a vision to improve public health and patient care. Over the years, Biomerieux has expanded its portfolio and expertise in microbiology, infectious diseases, and molecular diagnostics. With a strong commitment to innovation, the company has developed pioneering diagnostic solutions, including automated systems and reagents. Biomerieux serves various industries, including clinical laboratories, food testing, and pharmaceuticals, enabling timely and accurate disease detection and better treatment outcomes. With continuous research and development efforts, Biomerieux remains at the forefront of diagnostic solutions globally.
Biomerieux SA has achieved significant milestones throughout its history. The company has successfully developed and launched innovative diagnostic solutions for various diseases and conditions, contributing to improved patient care worldwide. Biomerieux SA also expanded its global presence by establishing strategic partnerships and acquiring complementary businesses. With a strong focus on research and development, the company has received numerous regulatory approvals for its diagnostic tests and devices. In addition, Biomerieux SA has garnered recognition for its commitment to sustainability and corporate social responsibility initiatives. These notable achievements highlight Biomerieux SA's dedication to advancing healthcare technology and delivering reliable diagnostic solutions.
Biomerieux SA is primarily present in countries and regions worldwide. With its global presence, Biomerieux has established a strong presence in numerous countries, including but not limited to, France, the United States, China, Brazil, India, and Japan. The company's operations span across these regions, allowing it to deliver its innovative diagnostic solutions and laboratory services to healthcare institutions, research facilities, and other related entities. Biomerieux's commitment to expanding its network ensures that its products and expertise are accessible to diverse populations, ultimately contributing to improved healthcare outcomes globally.
Biomerieux SA is committed to upholding strong values and a distinct corporate philosophy. The company prioritizes innovation, aiming to develop and provide cutting-edge solutions in the field of in vitro diagnostics. With a focus on healthcare, Biomerieux SA values quality, excellence, and patient well-being. By leveraging their expertise in microbiology, the company strives to improve public health worldwide. Biomerieux SA also emphasizes collaboration, teamwork, and ethical conduct among its employees. With a dedication to sustainable growth and a global outlook, Biomerieux SA continues to contribute to the advancement of diagnostic testing and improving patient outcomes.
Analysts currently set an average price target of 121.10 EUR for the Biomerieux stock (median: 121.38 EUR), implying +35.8 % versus the latest price. The consensus is based on 17 analyst ratings.
17 analysts currently rate the Biomerieux stock: 10 recommend buying, 7 holding and 0 selling. For 2026, analysts expect Biomerieux to generate revenue of 4.14 B EUR and earnings per share of 4.41 EUR.
The Biomerieux share (BIM.PA) is listed on 8 stock exchanges, including: London (0RUG.L), Frankfurt (EYWN.F), München (EYWN.MU), Düsseldorf (EYWN.DU), Wien (BIM.VI), Paris (BIM.PA).
The company Biomerieux SA was founded in 1963 and is headquartered in France. It is a leading manufacturer of in vitro diagnostics (IVD) and specializes in the development and production of solutions for the diagnosis of infectious diseases. Biomerieux operates several subsidiaries worldwide and employs approximately 12,000 people. Biomerieux's business model includes several divisions, including clinical diagnostics, industrial microbiology, food and water diagnostics, and veterinary diagnostics. In clinical diagnostics, the company offers a wide range of solutions for the diagnosis of infectious diseases. This includes test kits for the identification of bacteria, viruses, and fungi, PCR tests, and microbiology systems for determining antibiotic susceptibility. In industrial microbiology, Biomerieux specializes in the development of systems for the rapid identification of microorganisms in the food and beverage industry. The company also provides solutions for water quality control and industrial processes. The tests range from detecting contaminants in water samples to monitoring cleanroom conditions in the pharmaceutical industry. In the field of food and water diagnostics, Biomerieux is a global leader in the development of innovative solutions for detecting foodborne infections and toxins. The company offers a wide range of tests for monitoring food and drinking water. This also includes tests for controlling milk cultures and their fermentation. Veterinary diagnostics is another important area for Biomerieux. The company has developed a range of test kits for the diagnosis of animal diseases, including tests for the detection of infectious diseases in livestock. Biomerieux has become a key player in the field of medical diagnostics. The company invests heavily in research and development to develop new solutions for the diagnosis of infectious diseases. In addition, Biomerieux places great value on collaboration with other companies and research institutions to further improve the field of medical diagnostics. Overall, Biomerieux SA offers a wide range of solutions for the diagnosis of infectious diseases. The company is a leader in the fields of clinical diagnostics, industrial microbiology, food and water diagnostics, and veterinary diagnostics. Biomerieux continues to invest in research and development to develop innovative solutions that further improve the diagnosis of infectious diseases.
The expected revenue of Biomerieux is 4.14 B EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Biomerieux is 524.71 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Biomerieux is currently 20.23. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Biomerieux stock.
The price-to-sales ratio (P/S) of Biomerieux is currently 2.56. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Biomerieux stock.
The Eulerpool Quality Score for Biomerieux is 5/10.
The ISIN of Biomerieux is FR0013280286. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Biomerieux is A2DXZH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Biomerieux is BIM.PA. The ticker symbol is used to trade Biomerieux shares on the stock exchange.
Biomerieux stock
Biomerieux Peer Group
Biomerieux Ticker
Biomerieux FIGI
All fundamentals and in-depth analysis of Biomerieux
Our stock analysis for Biomerieux stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biomerieux. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.